UBS And JMP Securities Downgrade Achillion Pharmaceuticals, Inc. Following Johnson & Johnson Deal
May 21, 2015 at 10:58 AM EDT
Johnson & Johnson will pay Achillion Pharmaceuticals milestone payments totaling $1.1 billion throughout the development of its hepatitis C drug.
